Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
132 pending office actions • 70 art units • 120 examiners • 0 of 132 (0%) have an AI response strategy ready • 114 patents granted in the last 365 days
THE GENERAL HOSPITAL Corporation has 127 pending office actions in the Biotechnology & Pharmaceuticals technology area. These filings are spread across 65 distinct art units. The company interacts with 117 distinct examiners to prosecute these applications. This high count of 117 distinct examiners across 65 distinct art units indicates that the company's patent work is widely distributed across the patent office's staff and technical groups.
NILOOFAR RAHMANI is the busiest examiner for this portfolio, with 2 pending actions. This represents 2 of the 127 total pending office actions. For a practitioner, this data shows that the company rarely deals with the same examiner twice. With 117 distinct examiners involved, prosecution strategies must be highly customized for each matter, as there is almost no opportunity to build a consistent rapport with any single examiner across the 127 pending office actions.
Based on the USPTO statutory response window for each pending office action. 48 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 48 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (2%) |
| §101 + other | 20 (15%) |
| §103 only | 36 (27%) |
| §102 only | 1 (1%) |
| §112 only | 7 (5%) |
| Double-patenting only | 3 (2%) |
| Double-patenting + other | 15 (11%) |
| Multi-statute (no §101) | 46 (35%) |
| No statute on record | 2 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 2 | 77.5% | -2.9% |
| REILLY, SOPHIA JANE | 2 | 60.0% | +50.0% |
| PATEL, RISHI R | 2 | 82.6% | +2.3% |
| SHOMER, ISAAC | 2 | 63.1% | +30.5% |
| HERON, VELVET ELIZABETH | 2 | 52.4% | +43.3% |
| SKELDING, ZACHARY S | 2 | 59.8% | +41.1% |
| CASH, KAILEY ELIZABETH | 2 | 28.6% | +64.3% |
| LEE, YIE CHIA | 2 | 69.2% | +46.6% |
| POHNERT, STEVEN C | 2 | 12.5% | +18.3% |
| FETTEROLF, BRANDON J | 2 | 51.8% | +17.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996911 | SYSTEMS AND METHODS FOR ADMINISTERING A SMELL TEST FOR SARS CORONAVIRUSES AND COVID-19 | TOTH, KAREN E | 190d overdue |
| 18024179 | METHODS FOR IDENTIFYING CROSS-MODAL FEATURES FROM SPATIALLY RESOLVED DATA SETS | TRAN, DUY ANH | 132d overdue |
| 18014580 | INTERLEUKIN 33 (IL-33) INHIBITION FOR TREATMENT OF CANCER, FIBROSIS AND INFLAMMATION | HERNANDEZ, JACKSON J | 91d overdue |
| 16640942 | METHODS FOR MODULATING THE INTERACTION BETWEEN EWS-FLI1 AND BAF COMPLEXES | DENT, ALANA HARRIS | 87d overdue |
| 17636272 | SINGLE-CELL MODELING OF CLINICAL DATA TO DETERMINE RED BLOOD CELL REGULATION | VASSELL, MEREDITH ABBOTT | 85d overdue |
| 18008316 | SYSTEMS AND METHODS FOR NITRIC OXIDE GENERATION AND TREATMENT | RHEE, KELSEY | 73d overdue |
| 18818268 | ANTIBODIES WITH FC MODIFICATIONS AND METHODS OF USING THE SAME | GUSTILO, ESTELLA M | 72d overdue |
| 17923838 | Translation Blockers Repurposed for COVID-19 Therapy | ANDERSON, JAMES D | 72d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010695 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | FETTEROLF, BRANDON J | 160d overdue |
| 18021625 | PANCREATIC DUCTAL ADENOCARCINOMA SIGNATURES AND USES THEREOF | POHNERT, STEVEN C | 52d overdue |
| 17912272 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | FETTEROLF, BRANDON J | 7d |
| 17790535 | MICROFLUIDIC SYSTEMS AND METHODS FOR LOW-SHEAR ISOLATION OF RARE CELLS FROM LARGE SAMPLE VOLUMES | HERON, VELVET ELIZABETH | 55d |
| 17627975 | SELF-ASSEMBLED VACCINES AND COMBINATION THERAPIES FOR TREATING CANCER | LEE, YIE CHIA | 78d |
| 18730214 | IMMUNOMODULATORY LIPIDS AND USES THEREOF | REILLY, SOPHIA JANE | — |
| 18563575 | MMP13 AS A THERAPEUTIC TARGET FOR ALLERGIC INFLAMMATORY DISEASES | REILLY, SOPHIA JANE | — |
| 18290135 | MOLECULAR PROBES FOR IN VIVO DETECTION OF ALDEHYDES | SHOMER, ISAAC | — |
| Art Unit | Apps |
|---|---|
| 1683 | 7 |
| 3798 | 5 |
| 3797 | 5 |
| 3791 | 5 |
| 1691 | 4 |
| 3783 | 4 |
| 1645 | 4 |
| 1626 | 3 |
| 1627 | 3 |
| 3781 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19299570 | SYSTEM AND METHOD FOR DETECTING ACUTE BRAIN FUNCTION IMPAIRMENT | FERNANDEZ, KATHERINE L | 3798 | §102§103DP | Non-Final OA | — | Pending | Aug 14, 2025 |
| 19231352 | MINITUARIZED INTRAVASCULAR FLUORESCENCE-ULTRASOUND IMAGING CATHETER | MOHAMMED, SHAHDEEP | 3797 | §102DP | Non-Final OA | — | Pending | Jun 06, 2025 |
| 19127809 | SYSTEMS AND METHODS FOR LONG HAIR TRANSPLANTATION | HOAG, MITCHELL BRAIN | 3771 | §103 | Non-Final OA | — | Pending | May 07, 2025 |
| 19109980 | SYSTEMS AND METHODS FOR ATTENUATING ACOUSTIC WAVES | BARBOZA, MARCUS ALEXANDER | 2692 | §103 | Non-Final OA | — | Pending | Mar 07, 2025 |
| 19100916 | RETROGRADE TETHERED CAPSULE ENDOMICROSCOPY SYSTEMS AND METHODS | STARKEY, OLIVIA GRACE | 3795 | §103§112 | Non-Final OA | — | Pending | Feb 03, 2025 |
| 18881222 | SYSTEMS FOR ELECTROENCEPHALOGRAPY AND METHODS FOR MANUFACTURE OF THE SAME | SHOULDERS, ANNIE LEE | 3794 | §102§103§112 | Non-Final OA | — | Pending | Jan 03, 2025 |
| 18988259 | SYSTEMS AND METHODS FOR STIMULATED BRILLOUIN MICROSCOPY | NGUYEN, KEMAYA DEANN HUU | 2877 | §103 | Non-Final OA | — | Pending | Dec 19, 2024 |
| 18963054 | SYSTEM AND METHOD FOR ELECTROMAGNETIC INTERFERENCE MITIGATION FOR PORTABLE MRI SYSTEMS | CURRAN, GREGORY H | 2852 | §103 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18870158 | NEGATIVE PRESSURE LASER HANDPIECE | BAKKAR, AYA ZIAD | 3796 | §102§112 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18868614 | COMBINATION TREATMENT FOR ADENOCARCINOMA | SEUDIEU SEUDIEU, CARINE PATRICIA | 1626 | §102§103§112 | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18943466 | SYSTEMS, METHODS, AND MEDIA FOR MULTIPLE BEAM OPTICAL COHERENCE TOMOGRAPHY | UNDERWOOD, JARREAS C | 2877 | §103§112Other | Non-Final OA | — | Pending | Nov 11, 2024 |
| 18940226 | SYSTEM AND METHOD FOR EAR-ARRANGED TRANSCUTANEOUS VAGUS NERVE STIMULATION | DOWNEY, JOHN R | 3792 | §102§103§112 | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18862300 | SYSTEM FOR AND METHOD OF PLANNING AND REAL-TIME NAVIGATION FOR TRANSCRANIAL FOCUSED ULTRASOUND STIMULATION | NGUYEN, HIEN NGOC | 3797 | §103 | Non-Final OA | 29d | Pending | Nov 01, 2024 |
| 18862293 | SYSTEMS AND METHODS FOR ELECTROPHYSIOLOGICAL SIGNAL RECORDING AND POSITION OR MOTION MONITORING DURING MAGNETIC RESONANCE IMAGING | JASANI, ASHISH SHIRISH | 3798 | §102§103 | Final Rejection | 8d | Pending | Nov 01, 2024 |
| 18858643 | DEEP LEARNING BASED IMAGE RECONSTRUCTION | YANG, JIANXUN | 2662 | §103 | Non-Final OA | — | Pending | Oct 21, 2024 |
| 18856679 | MATERIALS AND METHODS FOR LUMINESCENCE-BASED CARBON DIOXIDE SENSING | CELESTINE, NYROBI I | 3798 | §102§103 | Non-Final OA | 49d overdue | Pending | Oct 14, 2024 |
| 18889325 | Methods and Compositions for Preserving Tissues and Organs | CLARKE, TRENT R | 1651 | §103§112 | Non-Final OA | — | Pending | Sep 18, 2024 |
| 18830080 | Complexes and Ligands | RAHMANI, NILOOFAR | 1691 | DP | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18845371 | SYSTEMS AND METHODS FOR IN VIVO CHARACTERIZATION OF TUBULAR SOFT TISSUES | NGUYEN, HUONG Q | 3791 | §101§103§112 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18818122 | DRUG ELUTING POLYMER COMPOSED OF BIODEGRADABLE POLYMERS APPLIED TO SURFACE OF MEDICAL DEVICE | FALKOWITZ, ANNA R | 1600 | §112DP | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18818268 | ANTIBODIES WITH FC MODIFICATIONS AND METHODS OF USING THE SAME | GUSTILO, ESTELLA M | 1646 | §103§112Other | Final Rejection | 72d overdue | Pending | Aug 28, 2024 |
| 18838347 | NEURAL PROGENITOR CELL COMPOSITIONS AND METHODS OF USING THE SAME | KASAYAN, KATRIEL BARCELLANO | 1634 | §101§103§112 | Non-Final OA | — | Pending | Aug 14, 2024 |
| 18730214 | IMMUNOMODULATORY LIPIDS AND USES THEREOF | REILLY, SOPHIA JANE | 1627 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18764634 | RNA-Guided Targeting of Genetic and Epigenomic Regulatory Proteins to Specific Genomic Loci | NOAKES, SUZANNE MARIE | 1656 | DP | Final Rejection | — | Pending | Jul 05, 2024 |
| 18726745 | SYSTEMS AND METHODS FOR IRRIGATING AN ANATOMIC SPACE | STIGELL, THEODORE J | 3783 | §102§103 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18762951 | SMALL MOLECULE PEPTIDOMIMETIC FOR THE TREATMENT OF TAUOPATHIES | SHAMEEM, GOLAM M | 1621 | §112 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18719106 | SYSTEM AND METHOD FOR CLINICAL DISORDER ASSESSMENT | OGLES, MATTHEW ERIC | 3791 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18663765 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INDUCING ANTIMICROBIAL INTRACELLULAR ACTIVITY AND FOR PREVENTING AND TREATING MICROBIAL INFECTIONS | RAHMANI, NILOOFAR | 1691 | §102 | Non-Final OA | — | Pending | May 14, 2024 |
| 18653324 | PENTAMIDINE ANALOGS | BURKETT, DANIEL JOHN | 1624 | §102§112 | Non-Final OA | — | Pending | May 02, 2024 |
| 18705368 | SYSTEM AND METHOD FOR INTRAOPERATIVE LIFETIME IMAGING | LI, JOHN DENNY | 3798 | §112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18704670 | ATRAUMATIC CATHETER | WRUBLESKI, MATTHEW JAMES | 3781 | §103§112 | Final Rejection | — | Pending | Apr 25, 2024 |
| 18645005 | USE OF MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION AND OVARIAN RESERVE PRESERVATION | BORGEEST, CHRISTINA M | 1675 | §112DPOther | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18703879 | METHODS AND COMPOSITION FOR THE TREATMENT OF PRADER-WILLI SYNDROME SYMPTOMS | DEVI, SARVAMANGALA | 1645 | §102§112DP | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18703198 | SYSTEMS AND METHODS FOR TRANSCATHETER SURGERY | LYNCH, ROBERT A | 3771 | §102§103 | Final Rejection | — | Pending | Apr 19, 2024 |
| 18699271 | ACCESS DEVICE | VU, QUYNH-NHU HOANG | 3783 | §102§103§112 | Non-Final OA | — | Pending | Apr 06, 2024 |
| 18618523 | DI-CUMYL PEROXIDE CROSSLINKING OF UHMWPE | BOYLE, ROBERT C | 1764 | §103Other | Non-Final OA | 15d overdue | Pending | Mar 27, 2024 |
| 18694815 | SMALL MOLECULE INHIBITORS OF TEAD-YAP | BAUER, BRIANNA LEE | 1623 | §102§103 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18605332 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | HUDSON, AMY ROSE | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18602622 | GENE THERAPY FOR TUBEROUS SCLEROSIS | VIVLEMORE, TRACY ANN | 1638 | §102§112DP | Non-Final OA | — | Pending | Mar 12, 2024 |
| 18688518 | METHODS FOR IDENTIFYING CROSS-MODAL FEATURES FROM SPATIALLY RESOLVED DATA SETS | RIVERA-MARTINEZ, GUILLERMO M | 2677 | §112 | Final Rejection | 22d overdue | Pending | Mar 01, 2024 |
| 18444413 | INJECTABLE SLURRIES AND METHODS OF MANUFACTURING AND USING THE SAME | ROSENTHAL, ANDREW S | 1613 | §103 | Non-Final OA | 63d | Pending | Feb 16, 2024 |
| 18681031 | MINIATURIZED MAGNETIC FIELD SENSOR | PATEL, RISHI R | 2896 | §103§112 | Non-Final OA | 14d | Pending | Feb 02, 2024 |
| 18417024 | INJECTABLE PROLONGED-RELEASE HYDROGEL FORMULATIONS OF TOLL-LIKE RECEPTOR AGONISTS FOR INTRATUMORAL INJECTION TO INCREASE IMMUNOTHERAPY RESPONSE | ANTHOPOLOS, PETER | 1611 | §103 | Final Rejection | 46d | Pending | Jan 19, 2024 |
| 18417527 | METHODS FOR REACTIVATING GENES ON THE INACTIVE X CHROMOSOME | WHITEMAN, BRIAN A | 1636 | §112DP | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18410620 | MOLECULAR ANALYSIS OF EXTRACELLULAR VESICLES (EVs) FOR THE PREDICTION AND MONITORING OF DRUG RESISTANCE IN CANCER | BELLAH, JEFFREY LAWRENCE | 1683 | §101§103§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18409614 | LIGHT-BASED SYSTEM AND METHOD FOR SHAPING AND TREATING HAIR | JENNESS, NATHAN JAY | 3733 | §103 | Final Rejection | — | Pending | Jan 10, 2024 |
| 18576696 | COMPOSITIONS AND METHODS FOR DECREASING PIGMENTATION | GREENE, IVAN A | 1619 | §102§103 | Non-Final OA | — | Pending | Jan 04, 2024 |
| 18396156 | Digital Analysis of Circulating Tumor Cells in Blood Samples | GROSS, CHRISTOPHER M | 1684 | §112Other | Final Rejection | — | Pending | Dec 26, 2023 |
| 18543705 | Regeneration of a Functional Pulmonary Vascular Bed | PYLA, EVELYN Y | 1633 | §103 | Final Rejection | — | Pending | Dec 18, 2023 |
| 18571154 | METHODS TO CHARACTERIZE FUNCTIONAL AND DYSFUNCTIONAL ACUTE INFLAMMATORY RESPONSES TO PATHOLOGIC PROCESSES | HOLCOMB, MARK | 3685 | §101§103 | Final Rejection | 56d overdue | Pending | Dec 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTHE GENERAL HOSPITAL Corporation has 132 pending office actions as of October 2026, spread across 70 art units and 120 examiners.
Niloofar Rahmani has the most, with 2 of THE GENERAL HOSPITAL Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.